- Home
- SVAC vs ALLO Comparison
SVAC vs ALLO Comparison
Compare SVAC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SVAC | ALLO |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.8M | 252.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SVAC | ALLO |
|---|---|---|
| Price | $10.57 | $2.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.27 |
| AVG Volume (30 Days) | 626.1K | ★ 6.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.06 | $0.86 |
| 52 Week High | $12.00 | $2.39 |
Technical Indicators
Market Signals| Indicator | SVAC | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 72.17 |
| Support Level | $10.46 | $1.56 |
| Resistance Level | $10.79 | $1.84 |
| Average True Range (ATR) | 0.25 | 0.19 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 38.46 | 98.98 |
Price Performance
Historical ComparisonAbout SVAC Spring Valley Acquisition Corp. III Class A Ordinary Shares
Spring Valley Acquisition Corp III is a blank check company.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.